StiCol Volume 365mg
Important Notice
Regulated medical device (EU MDR 2017/745). For sale exclusively to qualified healthcare professionals.
What this purchase includes
- Original productFrom the manufacturer or an official distributor, CE marked.
- Batch and expiry documentedRecorded per unit on the delivery note and the invoice.
- Controlled storageOur own Madrid warehouse, 12 to 18 °C under 24 h control.
- Dispatch in 24 to 48 hFrom Madrid, insured and with a tracking number.
- Reachable Monday to Friday9:00 to 17:00 by WhatsApp and email. People, not forms.
StiCol Volume is a lyophilised collagen biostimulator from CONTACKO Co., Ltd. (Seoul, South Korea) formulated with poly-L-lactic acid microspheres. Its distinguishing feature among PLLA biostimulators is the rapid dilution protocol: the manufacturer describes a hydration time of approximately one hour compared with the 8–12 hours of the conventional method, as well as the option of reconstituting with its own slightly cross-linked hyaluronic acid additive SS-A instead of physiological saline.
- PLLA 150 mg per vial
- Vial 365 mg of lyophilised powder
- Rapid dilution approx. 1 hour
- Plane subcutaneous
- Diluent physiological saline or SS-A
Composition and technology
- Poly-L-lactic acid (PLLA): 150 mg per vial, in microspheres of approximately 50 µm.
- Sodium carboxymethylcellulose: 90 mg — suspending agent.
- Mannitol: 125 mg — bulking agent and cryoprotectant for lyophilisation.
- Total vial content: 365 mg of lyophilised powder.
- Micelle technology: the manufacturer attributes the product's reduced hydration time to its proprietary micelle-formation process.
- Mechanism: the PLLA microspheres induce a tissue remodelling response that stimulates collagen synthesis by dermal fibroblasts. The polymer is degraded by hydrolysis to lactic acid and eliminated metabolically; the clinical result corresponds to the newly formed collagen, not to the implanted material.
- Origin: synthetic polymer. It contains no protein of animal or human origin.
Position within the StiCol range
| StiCol Volume | Volumising PLLA — 150 mg of PLLA in a 365 mg vial. Subcutaneous plane. Volume restoration and correction of folds. |
|---|---|
| StiCol Soft | Micronised PLLA — 50 mg of PLLA in a 120 mg vial. Hypodermic plane. Skin quality and firmness. |
| SS-A | Slightly cross-linked 1 % hyaluronic acid additive, used as an alternative to physiological saline in reconstitution. |
This information sheet corresponds to StiCol Volume, the volumising variant of the range.
Indications and treatment areas
Injectable biostimulator indicated for the progressive restoration of facial volume in adult patients.
- Age-related volume loss
- Cheekbones and temporal region
- Nasolabial sulcus and marionette lines
- Correction of the facial contour
- Skin laxity and loss of firmness
Reconstitution and treatment protocol
Reconstitution is the critical step of this product. With PLLA biostimulators, incomplete hydration or a non-homogeneous suspension are the main cause of late nodules.
- Diluent: sterile physiological saline or the manufacturer's own SS-A hyaluronic acid additive solution.
- Anaesthesia: the manufacturer allows for replacing 1 ml of the diluent with 1 ml of lidocaine, at the operator's discretion.
- Timing of preparation: the vial may be reconstituted on the day before the procedure or on the same day.
- Hydration time: the manufacturer describes a rapid method of approximately 1 hour —presented as "rapid dilution in 50 minutes"— and a conventional method of 8 to 12 hours.
- Agitation: shake gently for 10 minutes before application, until a homogeneous suspension is obtained.
- Injection plane: subcutaneous tissue.
- Post-treatment massage: massage the treated area after the session to distribute the microspheres evenly.
- Onset of the result: progressive, over the weeks following each session.
The manufacturer does not publish a reconstitution volume in millilitres, a fixed number of sessions or a defined interval between them. Take those parameters from the instructions for use supplied with the batch.
Technical data
| Manufacturer | CONTACKO Co., Ltd. — Seoul, South Korea |
|---|---|
| Active substance | Poly-L-lactic acid (PLLA) 150 mg |
| Excipients | Sodium carboxymethylcellulose 90 mg, mannitol 125 mg |
| Microsphere size | Approx. 50 µm |
| Presentation | 1 vial of 365 mg of lyophilised powder |
| Diluent | Physiological saline or SS-A solution (HA 1 %) |
| Hydration | Rapid method approx. 1 hour / conventional method 8–12 hours |
| Injection plane | Subcutaneous tissue |
| Use | Qualified healthcare professionals with specific training in PLLA only |
Storage and pack contents
- Storage: store the lyophilised vial in its original packaging, protected from light and moisture, under the conditions stated on the pack.
- Do not use after the expiry date stated on the pack.
- Sterile single-use product. Do not reuse or re-sterilise.
- The pack contains: 1 vial of 365 mg of lyophilised powder and instructions for use. The diluent, syringes and needles are not included.
- Carry out the reconstitution under aseptic conditions.
Contraindications and warnings
Contraindications: known hypersensitivity to polylactic acid or to any of the excipients; active skin infection or inflammation in the treatment area; pregnancy and breastfeeding; active autoimmune disease; tendency to hypertrophic or keloid scarring; under 18 years of age.
Warnings specific to PLLA biostimulators: do not inject into the lips or into the periorbital region. Injection that is too superficial, incomplete hydration of the product, a non-homogeneous suspension or insufficient massage after the session are associated with the formation of late nodules and papules. Do not overcorrect: the effect is not immediate and must be assessed weeks later, not in the same session.
Never inject intravascularly. Always consult the instructions for use included in the pack before treatment.
Product intended exclusively for qualified healthcare professionals with specific training in polylactic acid biostimulators. Technical information based on documentation from the manufacturer CONTACKO Co., Ltd. and from its official distribution. The reconstitution and application parameters must be taken from the instructions for use supplied with each batch; this information sheet does not replace them.